Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 121 to 130 of 471 total matches.
Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
prolongation and cardiac
arrythmias.1,2 The macrolide antibiotics erythromycin
and azithromycin ...
The FDA has approved Gimoti (Evoke), a nasal
spray formulation of the dopamine-2 (D2) receptor
antagonist metoclopramide, for relief of symptoms in
adults with acute and recurrent diabetic gastroparesis.
Metoclopramide (Reglan, and generics) has been
available for years in conventional and orally-disintegrating
tablets and in an injectable formulation.
It is the only drug that is FDA-approved for treatment
of diabetic gastroparesis.
Cladribine (Mavenclad) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019 (Issue 1577)
(PML)
compared to other MS treatments.1-3
Oral fingolimod (Gilenya), teriflunomide (Aubagio ...
The FDA has approved cladribine (Mavenclad – EMD
Serono), a purine antimetabolite, for oral treatment
of adults with relapsing forms of multiple sclerosis
(MS), including relapsing-remitting disease and
active secondary progressive MS (SPMS), who
cannot tolerate or have had an inadequate response
to other drugs indicated for treatment of MS. It is
not recommended for use in patients with clinically isolated syndrome (CIS). IV cladribine, which is FDA-approved
for treatment of hairy cell leukemia, has been
used off-label for treatment of MS.
Expanded Table: Some Drugs for Smoking Cessation (online only)
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
)
Nicotine transdermal patch –
generic
NicoDerm CQ (GSK)
7, 14, 21 mg/24 hr
patches
1 patch/day ...
View the Expanded Table: Some Drugs for Smoking Cessation
IV Artesunate for Severe Malaria
The Medical Letter on Drugs and Therapeutics • Aug 10, 2020 (Issue 1604)
in children and adults. It has been available
from the CDC on a compassionate use basis since
2007.1 ...
Artesunate for injection (Amivas LLC), a semi-synthetic
artemisinin derivative, is now approved
by the FDA for initial (induction) treatment of severe
malaria in children and adults. It has been available
from the CDC on a compassionate use basis since
2007. Artemether/lumefantrine (Coartem), another
artemisinin-based drug, was approved earlier for oral
treatment of uncomplicated Plasmodium falciparum
malaria. IV artesunate is now the only FDA-approved
injectable antimalarial drug available in the US; IV
quinidine has been discontinued.
An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019 (Issue 1566)
.
Pronunciation Key
Symjepi: sim jep’ ee
Table 1. Epinephrine Products for Anaphylaxis
Epinephrine Injection ...
The FDA has approved a manually
injected, single-dose, prefilled
epinephrine syringe (Symjepi –
Adamis/Sandoz) for emergency
treatment of anaphylaxis. The new
device is approved in 0.3- and
0.15-mg strengths for treatment of
patients weighing ≥30 kg and 15 to
30 kg, respectively; only the 0.3-mg
strength is currently available.
According to Sandoz, Symjepi will be made available
first to institutions and later to the retail market.
COVID-19 Vaccine Comparison Chart (online only)
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
doses (0.3 mL)
21 days apart 2 doses (0.5 mL)
28 days apart 1 dose (0.5 mL)
2 doses
4-12 weeks ...
View the COVID-19 Vaccine Comparison Chart
Safinamide (Xadago) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017 (Issue 1529)
can be problematic as the disease
advances and higher doses are required.1-3 Adding
a dopamine ...
The FDA has approved the monoamine oxidase
type B (MAO-B) inhibitor safinamide (Xadago – US
Worldmeds) as an adjunct to levodopa/carbidopa
for management of "off" episodes in patients with
Parkinson’s disease (PD). It is the first reversible
MAO-B inhibitor to be approved for this indication.
Selegiline (Eldepryl, and others) and rasagiline
(Azilect, and generics), two irreversible MAO-B
inhibitors, have been used alone and as adjuncts to
levodopa/carbidopa for many years. Safinamide is
not approved for use as monotherapy.
Rifamycin (Aemcolo) for Treatment of Travelers' Diarrhea
The Medical Letter on Drugs and Therapeutics • Mar 11, 2019 (Issue 1567)
of TD.1) Most patients are infected via fecaloral
transmission from contaminated food or water ...
The FDA has approved rifamycin (Aemcolo – Cosmo/
Aries), a minimally absorbed oral antibiotic, for
treatment of adults with travelers' diarrhea (TD)
caused by noninvasive strains of Escherichia coli. It
is not recommended for treatment of diarrhea that is
complicated by fever and/or bloody stools. Topical
and injectable formulations of rifamycin have been
used in Europe for other indications for many years.
Talicia - A 3-Drug Combination for Helicobacter pylori Infection
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
patient adherence to multidrug
regimens.1 When available, susceptibility testing
should be used to guide ...
The FDA has approved a fixed-dose combination
of omeprazole, amoxicillin, and rifabutin (Talicia –
RedHill) for treatment of Helicobacter pylori infection
in adults. Talicia is the first rifabutin-based product to
be approved for this indication.
Oriahnn for Fibroid-Associated Heavy Menstrual Bleeding
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
) has been
available since 2018 for treatment of moderate to
severe pain associated with endometriosis.1 The
GnRH ...
Oriahnn (Abbvie), a fixed-dose combination of the
gonadotropin-releasing hormone (GnRH) receptor
antagonist elagolix, the estrogen estradiol, and the
progestin norethindrone acetate copackaged with
elagolix alone, has been approved by the FDA for oral
treatment of heavy menstrual bleeding associated
with uterine leiomyomas (fibroids) in premenopausal
women. It is the first product to be approved in the
US for this indication. Elagolix (Orilissa) has been
available since 2018 for treatment of moderate to
severe pain associated with endometriosis. The
GnRH receptor antagonist...